Alzheimer's Disease Viewed as a Neurovascular Inflammatory Disorder

阿尔茨海默病被视为神经血管炎性疾病 项目总结/摘要 阿尔茨海默病（AD）是一种缺乏有效治疗的毁灭性神经退行性疾病。最 测试AD的长期淀粉样蛋白假说的临床试验显示出很少的希望。小说的未来 针对该疾病的其他病理生理过程的治疗是不确定的。越来越多的证据 支持神经血管炎症作为AD发病的主要致病或加重因素的作用， 进展然而，科学界尚未将AD标记为血管疾病，问题仍然存在 关于神经血管炎症作为潜在治疗靶点的可行性。为了解决这一争议 迎面而来的是，纽约科学院将举办为期一天的研讨会和联播网络研讨会， “阿尔茨海默病被视为神经血管炎性疾病”12/6/2016。这个目标 研讨会的目的是评估临床和临床前数据，研究神经血管病理学在 AD的发展。理解如何临床检验基于血管的假设的关键障碍 AD的治疗将被讨论，包括用于监测疾病进展的最新成像进展。 此外，关于分子和生理过程的新兴科学可以作为靶点， 将提出新的治疗方法。本次研讨会将填补会议领域的一个重要空白， 就AD和血管疾病研究之间的协同作用进行了重点深入的讨论， 建立在最近定义的需要更好地了解AD和血管的神经血管失调， 痴呆（36）。这一具有里程碑意义的事件将联合200人的基础，翻译和临床研究人员- 沿着来自学术界、工业界、政府和非营利组织的全球网络研讨会参与者 组织，致力于神经退行性疾病和血管疾病，努力了解， 预防和治疗AD和血管性痴呆如小血管病（SVD）。会议将讨论 5个中心目标：（i）阐明AD中遗传信息与神经血管病理学之间的关系 和SVD;（ii）探索对血管功能和CNS至关重要的新分子靶点和生理过程 （iii）描述神经血管失调的临床方面 以及AD和SVD中的炎症，并鉴定基于血管的机制的生物标志物;（iv）鉴定 知识差距和未来研究需要在预防和治疗AD方面取得突破;以及（v） 展示和鼓励早期职业，女性和代表性不足的少数民族的参与 研究人员通过简短的会谈，海报展示和奖品，旅行奖学金，和折扣注册。 此外，NINDS传播信息的具体目标将通过同步网络研讨会实现 并出版一份持久的开放获取学院电子简报。一个合作的，多学科的 这种方法对于满足AD患者的迫切需求至关重要。为此，本次活动将 从广泛的角度考虑AD的新疾病机制和治疗靶点。

Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder PROJECT SUMMARY / ABSTRACT Alzheimer’s disease (AD) is a devastating neurodegenerative disorder lacking effective treatments. Most clinical trials testing the long-standing amyloid hypothesis of AD have shown little promise. The future of novel treatments targeting other pathophysiological processes in the disease is uncertain. Growing evidence supports a role for neurovascular inflammation as a major causative or exacerbating factor in AD onset and progression. However, the scientific community has yet to label AD a vascular disease and questions remain about the viability of neurovascular inflammation as a potential therapeutic target. To address this controversy head-on, the New York Academy of Sciences will present a 1-day symposium and simulcast Webinar, “Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder” on 12/6/2016. The goal of this symposium is to evaluate clinical and preclinical data investigating the role of neurovascular pathology in the development of AD. Critical barriers to understanding how to clinically test vascular-based hypotheses for the treatment of AD will be discussed, including recent imaging advances for monitoring disease progression. Moreover, emerging science on molecular and physiological processes that can be leveraged as targets for novel therapeutics will be presented. This symposium will fill an important gap in the conference landscape, presenting a focused, in-depth discussion on the synergies between AD and vascular disease research, building upon the recently defined need to better understand neurovascular dysregulation in AD and vascular dementia (36). This landmark event will unite 200 in-person basic, translational, and clinical researchers — along with a global audience of Webinar participants — from academia, industry, government, and non-profit organizations, working on neurodegenerative disorders and vascular disease in an effort to understand, prevent, and treat AD and vascular dementias such as small vessel disease (SVD). Sessions will address 5 central aims: (i) Elucidate the relationship between genetic information and neurovascular pathology in AD and SVD; (ii) Explore novel molecular targets and physiological processes critical to vascular function and CNS health, using human studies and animal models; (iii) Describe clinical aspects of neurovascular dysregulation and inflammation in AD and SVD and identify biomarkers for vascular-based mechanisms; (iv) Identify knowledge gaps and future research required for breakthroughs in prevention and treatment of AD; and (v) Showcase and encourage the participation of Early-Career, female, and Underrepresented Minority investigators via short talks, poster presentations and prizes, travel fellowships, and discounted registration. In addition, the NINDS’ specific goal of disseminating information will be met through a simulcast Webinar and publication of an enduring open-access Academy eBriefing. A collaborative, multidisciplinary approach will be critical to meeting the urgent unmet need for AD patients. To that end, this event will consider new disease mechanisms and therapeutic targets for AD, from a broad range of perspectives.